86884-87-9

Basic information

• Product Name: (4RS)-4-hydroxymethyl-2,2,4-trimethyl-1,3-dioxolane
• Synonyms: (4RS)-4-hydroxymethyl-2,2,4-trimethyl-1,3-dioxolane
• CAS NO: 86884-87-9
• Molecular Weight: 146.186
• Mol File: 86884-87-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (4RS)-4-hydroxymethyl-2,2,4-trimethyl-1,3-dioxolane(CAS DataBase Reference)
• NIST Chemistry Reference: (4RS)-4-hydroxymethyl-2,2,4-trimethyl-1,3-dioxolane(86884-87-9)
• EPA Substance Registry System: (4RS)-4-hydroxymethyl-2,2,4-trimethyl-1,3-dioxolane(86884-87-9)

Safety Data

• Hazardous Substances Data: 86884-87-9(Hazardous Substances Data)

Upstream product

• 25245-58-3 2-methylpropane-1,2,3-triol 
• 77-76-9 2,2-dimethoxy-propane 
• 67-64-1 acetone 

Downstream Products

• 79243-92-8 (S)-(-)-2,2,4-trimethyl-1,3-dioxolane-4-carboxaldehyde 
• 86940-97-8 (R)-(+)-2,2,4-trimethyl-4-(hydroxymethyl)-1,3-dioxolane 
• 86940-98-9 (S)-(-)-2,2,4-trimethyl-4-(hydroxymethyl)-1,3-dioxolane 
• 149563-84-8 <(S)-2,2,4-trimethyl-1,3-dioxolan-4-yl>methyl butyrate 
• 1132650-61-3 dodecanoic acid ((R)-2,2,4-trimethyl-14,3-dioxolan-4-yl-methyl) ester 
• 1132650-60-2 succinic acid mono-((R)-2,2,4-trimethyl-1,3-dioxolan-4-yl-methyl) ester 
• 32378-61-3 4-benzyloxymethyl-2,2,4-trimethyl-1,3-dioxolane 
• 133868-48-1 <(S)-2,2,4-trimethyl-1,3-dioxolan-4-yl>methyl p-toluenesulfonate 
• 956599-27-2 (R,S)-4-nitro-3-(2,2,4-trimethyl-[1,3]dioxolan-4-ylmethoxy)-phenol 
• 111219-30-8 Phenyl-acetic acid 2,2,4-trimethyl-[1,3]dioxolan-4-ylmethyl ester 
• 123044-87-1 4-(p-toluenesulfonyloxymethyl)-2,2,4-trimethyl-1,3-dioxolane 
• 123920-07-0 5-Hydroxy-2,2-dimethoxy-5-(2,2,4-trimethyl-1,3dioxolan-4-yl)pentan-3-one 

Relevant articles and documents

4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

Development of a multikilogram synthesis of a chiral epoxide precursor to a CCR1 antagonist. Use of in situ monitoring for informed optimisation via fragile intermediates

The optimisation and scale up of a manufacturing route to a key intermediate, acetic acid 4-acetylamino-3-(2-methyl-oxiranyl- methoxy)phenyl ester (2), utilising a SNAr coupling, the hydro- genation of a nitro moiety and the conversion of a chi

Facile synthesis of C2-symmetric chiral crown ethers with two reactive hydroxymethyl groups

Two C2-symmetric chiral crown ethers, (2S,12S)-2,12- bis(hydroxymethyl)-2,12-dimethyl-18-crown-6 and (2R,9R)-2,9-bis(hydroxymethyl)- 2,9-dimethyl-18-crown-6 were synthesized from a chiral subunit, [(45)-2,2,4-trirnethyl-1,3-dioxolane-4-yl]methanol, at high enantiomeric purity over several steps. This synthetic method offers the potential to construct a variety of C2-symmetric chiral crown ethers using diverse combinations of building blocks. Georg Thieme Verlag Stuttgart.